RET Fusion Positive
Drug | Drug Name | Drug Description |
---|---|---|
DB15685 | Selpercatinib | A RET receptor tyrosine kinase inhibitor for the treatment of RET-driven non-small cell lung cancer, medullary thyroid cancer, and thyroid cancer in appropriate patient populations. |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB11791 | Capmatinib | 2 | Terminated | 1 |
DB09063 | Ceritinib | 2 | Terminated | 1 |
DB11986 | Entrectinib | 2 | Terminated | 1 |
DB08896 | Regorafenib | 2 | Terminated | 1 |